gemfibrozil has been researched along with Dyslipidemia in 29 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " After 12 weeks' treatment, the pioglitazone group showed a highly significant reduction in body weight (83±10." | 9.24 | Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia. ( Akhtar, L; Hussain, M; Shad, MN, 2017) |
| "To assess the lipid-modifying and pleiotropic effects of drugs of the statin group (simvastatin and pravastatin) and the fibrate group (gemfibrozil) in dyslipidemia patients." | 9.12 | Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia. ( Doncheva, NI; Nikolov, KV; Vassileva, DP, 2006) |
| " simvastatin and gemfibrozil in type 2 diabetic patients with dyslipidemia in Pakistani population." | 9.11 | Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes. ( Amir, K; Ashraf, R; Shaikh, AR, 2005) |
| "Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome." | 7.73 | Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. ( Kovanen, PT; Manninen, V; Mänttäri, M; Tenkanen, L; Virkkunen, H, 2006) |
| " After 12 weeks' treatment, the pioglitazone group showed a highly significant reduction in body weight (83±10." | 5.24 | Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia. ( Akhtar, L; Hussain, M; Shad, MN, 2017) |
| "To assess the lipid-modifying and pleiotropic effects of drugs of the statin group (simvastatin and pravastatin) and the fibrate group (gemfibrozil) in dyslipidemia patients." | 5.12 | Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia. ( Doncheva, NI; Nikolov, KV; Vassileva, DP, 2006) |
| " simvastatin and gemfibrozil in type 2 diabetic patients with dyslipidemia in Pakistani population." | 5.11 | Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes. ( Amir, K; Ashraf, R; Shaikh, AR, 2005) |
| " Of all the medications currently available, the fibric acid derivatives have a cholesterol lowering profile that is most likely to be effective in obese children with the high TG/low HDL phenotype and data from a recently published study of gemfibrozil in children with metabolic syndrome are promising." | 4.89 | Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents. ( Jellerson, KD; Kennedy, MJ; Snow, MZ; Zacchetti, ML, 2013) |
| "Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome." | 3.73 | Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. ( Kovanen, PT; Manninen, V; Mänttäri, M; Tenkanen, L; Virkkunen, H, 2006) |
| " An unusual dose-response pattern was observed in that at 6 mg/day CP-778,875 only increased HDL cholesterol by 3% and decreased HDL(2) cholesterol by 24%." | 2.73 | Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus. ( Contant, CF; Francone, OL; Gao, X; Lewin, AJ; Nguyen, TT; Terra, SG, 2008) |
| "Since dyslipidemia is common in diabetes and is associated with increased cardiovascular risk, we tested the hypothesis that Thr-54 is associated with increased cardiovascular risk in patients with diabetes." | 2.73 | Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT). ( Bloomfield, H; Brousseau, ME; Collins, D; Georgopoulos, A; O'Connor, JJ; Ordovas, JM; Robins, SJ; Schaefer, EJ, 2007) |
| "Low HDL-C levels are common in type 2 diabetes but are not currently recommended as a target for treatment because of the lack of definitive cardiovascular outcome studies supporting this goal, and because of the difficulty in raising HDL-C." | 2.46 | Management of dyslipidemia in people with type 2 diabetes mellitus. ( Dunn, FL, 2010) |
| "Metformin has a greater impact on BMI in responders of metformin compared to nonresponders." | 1.43 | The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin. ( Alizadeh, A; Kashi, Z; Kianmehr, A; Mahrooz, A, 2016) |
| " Patients were stratified according to statin and dosage to identify against-label combination use (e." | 1.38 | Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions. ( Alford, JC; Allen, RR; Nair, KV; Saseen, JJ, 2012) |
| "Monotherapy for the treatment of dyslipidemias is commonly insufficient to achieve all lipid targets recommended by current guidelines." | 1.33 | [Drug combinations: statins and fibrates]. ( Xavier, HT, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (55.17) | 29.6817 |
| 2010's | 13 (44.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sashidhara, KV | 3 |
| Kumar, A | 4 |
| Bhatia, G | 6 |
| Khan, MM | 2 |
| Khanna, AK | 3 |
| Saxena, JK | 1 |
| Ghosh, S | 1 |
| Misra, AK | 1 |
| Maurya, RA | 2 |
| Sharma, S | 2 |
| Ahmad, P | 1 |
| Singh, AB | 1 |
| Srivastava, AK | 2 |
| Tripathi, VD | 1 |
| Srivastava, SP | 1 |
| Tamrakar, AK | 1 |
| Kumar, M | 1 |
| Sonkar, R | 2 |
| Palnati, GR | 1 |
| Avula, SR | 1 |
| Awasthi, C | 1 |
| Fruchart, JC | 1 |
| Santos, RD | 1 |
| Hussain, M | 1 |
| Shad, MN | 1 |
| Akhtar, L | 1 |
| Kennedy, MJ | 1 |
| Jellerson, KD | 1 |
| Snow, MZ | 1 |
| Zacchetti, ML | 1 |
| Kashi, Z | 1 |
| Mahrooz, A | 1 |
| Kianmehr, A | 1 |
| Alizadeh, A | 1 |
| Terra, SG | 1 |
| Francone, OL | 1 |
| Contant, CF | 1 |
| Gao, X | 1 |
| Lewin, AJ | 1 |
| Nguyen, TT | 1 |
| Silverberg, MJ | 1 |
| Leyden, W | 1 |
| Hurley, L | 1 |
| Go, AS | 1 |
| Quesenberry, CP | 1 |
| Klein, D | 1 |
| Horberg, MA | 1 |
| Nolan, DP | 1 |
| O'Connor, MB | 1 |
| O'Connor, C | 1 |
| Moriarty, M | 1 |
| O'Leary, A | 1 |
| Bergin, C | 1 |
| Dunn, FL | 1 |
| Amend, KL | 1 |
| Landon, J | 1 |
| Thyagarajan, V | 1 |
| Niemcryk, S | 1 |
| McAfee, A | 1 |
| Alford, JC | 1 |
| Saseen, JJ | 1 |
| Allen, RR | 1 |
| Nair, KV | 1 |
| Shaikh, Q | 1 |
| Kamal, AK | 1 |
| Lee, CY | 1 |
| Huang, KH | 1 |
| Lin, CC | 1 |
| Tsai, TH | 1 |
| Shih, HC | 1 |
| Ashraf, R | 1 |
| Amir, K | 1 |
| Shaikh, AR | 1 |
| Chironi, G | 1 |
| Simon, A | 1 |
| Gariepy, J | 1 |
| Balice, M | 1 |
| Del-Pino, M | 1 |
| Levenson, J | 1 |
| Saseen, J | 1 |
| Tweed, E | 1 |
| Crawford, P | 1 |
| Xavier, HT | 1 |
| Tenkanen, L | 1 |
| Mänttäri, M | 1 |
| Kovanen, PT | 1 |
| Virkkunen, H | 1 |
| Manninen, V | 1 |
| Georgopoulos, A | 1 |
| Bloomfield, H | 1 |
| Collins, D | 1 |
| Brousseau, ME | 1 |
| Ordovas, JM | 1 |
| O'Connor, JJ | 1 |
| Robins, SJ | 1 |
| Schaefer, EJ | 1 |
| Patel, J | 1 |
| Rizzo, M | 1 |
| Berneis, K | 1 |
| Doncheva, NI | 1 |
| Nikolov, KV | 1 |
| Vassileva, DP | 1 |
| Chrysohoou, C | 1 |
| Singh, S | 1 |
6 reviews available for gemfibrozil and Dyslipidemia
| Article | Year |
|---|---|
SPPARM alpha: the Lazarus effect.
Topics: Animals; Atherosclerosis; Benzoxazoles; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofib | 2019 |
Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents.
Topics: Adolescent; Cardiovascular Diseases; Child; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Fibri | 2013 |
Management of dyslipidemia in people with type 2 diabetes mellitus.
Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ez | 2010 |
Dyslipidaemia in diabetes.
Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; D | 2006 |
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
Topics: Bezafibrate; Clofibric Acid; Dyslipidemias; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipi | 2007 |
Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials a | 2006 |
5 trials available for gemfibrozil and Dyslipidemia
| Article | Year |
|---|---|
Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia.
Topics: Adult; Aged; Body Mass Index; Body Weight; Dyslipidemias; Female; Gemfibrozil; Humans; Hypoglycemic | 2017 |
Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein B-100; C-Reactive Protein; Cholesterol, HDL; Diabete | 2008 |
Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Gemfibr | 2005 |
Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT).
Topics: Aged; Codon; Diabetes Mellitus; Dyslipidemias; Fatty Acid-Binding Proteins; Gemfibrozil; Genetic Pre | 2007 |
Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia.
Topics: Dyslipidemias; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravast | 2006 |
18 other studies available for gemfibrozil and Dyslipidemia
| Article | Year |
|---|---|
Antidyslipidemic and antioxidative activities of 8-hydroxyquinoline derived novel keto-enamine Schiffs bases.
Topics: Amines; Animals; Antioxidants; Dyslipidemias; Fluorescence; Heparin; Hydroxyl Radical; Hydroxyquinol | 2009 |
Syntheses and evaluation of glucosyl aryl thiosemicarbazide and glucosyl thiosemicarbazone derivatives as antioxidant and anti-dyslipidemic agents.
Topics: Animals; Antioxidants; Drug Evaluation, Preclinical; Dyslipidemias; Hypolipidemic Agents; Rats; Semi | 2009 |
Pyranocoumarins: a new class of anti-hyperglycemic and anti-dyslipidemic agents.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dyslipidemias; Hypoglycemic Agents; Lipid M | 2009 |
Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Design; Dyslipidemias; Glycogen Phosphorylase; Hypogl | 2010 |
Novel coumarin derivatives as potential antidyslipidemic agents.
Topics: Coumarins; Dyslipidemias; Humans | 2010 |
Coumarin chalcone fibrates: a new structural class of lipid lowering agents.
Topics: Animals; Chalcones; Coumarins; Dyslipidemias; Male; Molecular Structure; Polyethylene Glycols; Rats; | 2013 |
The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.
Topics: Adult; Atorvastatin; Biological Transport; Blood Glucose; Blood Pressure; Body Mass Index; Cholester | 2016 |
Summaries for patients. Response to cholesterol-lowering drugs in patients with and without HIV infection.
Topics: Anti-HIV Agents; Cholesterol, LDL; Dyslipidemias; Female; Gemfibrozil; HIV Infections; Humans; Hypol | 2009 |
Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection.
Topics: Anti-HIV Agents; Cholesterol, LDL; Cohort Studies; Dyslipidemias; Female; Gemfibrozil; HIV Infection | 2009 |
HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies.
Topics: Anti-HIV Agents; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Dy | 2010 |
Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
Topics: Cohort Studies; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Electronic Health Reco | 2011 |
Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Topics: Cohort Studies; Dose-Response Relationship, Drug; Drug Labeling; Drug Therapy, Combination; Dyslipid | 2012 |
HDL cholesterol--how do I raise my patients good cholesterol?
Topics: Cholesterol, HDL; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Evidence-Based | 2012 |
A neutral risk on the development of new-onset diabetes mellitus (NODM) in Taiwanese patients with dyslipidaemia treated with fibrates.
Topics: Adult; Diabetes Complications; Diabetes Mellitus; Dyslipidemias; Female; Fenofibrate; Gemfibrozil; H | 2012 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Aci | 2005 |
Clinical inquiries. What are effective medication combinations for dyslipidemia?
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medic | 2006 |
[Drug combinations: statins and fibrates].
Topics: Age Factors; Clofibric Acid; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; Ge | 2005 |
Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study.
Topics: Coronary Disease; Double-Blind Method; Dyslipidemias; Follow-Up Studies; Gemfibrozil; Humans; Hypoli | 2006 |